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Strategies to Demonstrate the Value of Pharmacists’
Cognitive Services
__________________________________________
Health Partners, which is a managed care plan in Philadelphia, and the Office of
Health Policy and Clinical Outcomes (OHP), participated in a continuing education
program for pharmacists at Temple University. The purpose of this program was to
educate pharmacists about how to measure the effect of cognitive services that they
provide to asthmatics so that fees for these services can be established. Cognitive
services include counseling patients, profiling medications, and performing any
function other than dispensing medicines. Michael Schaffer, PharmD, MBA, Director
of Health Policy and Clinical Outcomes at Health Partners (and a former fellow of the
OHP), and Amy Drabinski, PharmD, MBA, a current health outcomes research fellow
at Knoll Pharmaceuticals, presented outcomes research as it applies to asthma. They
focused on the importance of the pharmacist’s role in measuring and documenting
asthma-related outcomes.
Dr. Schaffer introduced the concept of Economic, Clinical and Humanistic Outcomes
(ECHO), which proves useful in helping pharmacists to justify cognitive services.
Economic outcomes involve both direct medical costs of treating the disease (costs of
physician visits, prescriptions, emergency room visits) and indirect medical costs
(transportation and lost productivity). Clinical outcomes are medical events that
occur as result of a disease and include symptoms and hospitalizations. Humanistic
outcomes measure a patient’s functional status or quality of life (QOL). The ECHO
model recognizes the importance of systematically collecting outcomes data to
determine the value of the effectiveness and consequences of treatment
alternatives.1
Asthma is costly to the American healthcare system.2 Pharmacists can have a
positive impact on quality of life and cost of treatment for asthmatics by participating
in disease management programs and through one-on-one counseling. Although
pharmacists spend a significant amount of time providing cognitive services to
asthmatics, they encounter obstacles in justifying reimbursement for these services.
Pharmacists often struggle with quantifying the impact that counseling patients and
profiling their medications has on a patient’s condition. To justify reimbursement for
cognitive services, pharmacists need to learn how to measure the difference that
their actions make on patients with asthma. They can do this by looking at the
influence that intervention and counseling have on economic, clinical, and humanistic
(QOL) outcomes.
Humanistic outcomes are difficult to measure. Dr. Drabinski discussed methods of
measuring them through two common types of questionnaires. Both questionnaires
measure QOL, although one is generic, and one is disease-specific.
The two generic instruments that are used most often are the SF-36 and the
Sickness Index Profile (SIP). Measuring QOL with generic questionnaires allows
comparisons to be made between patients across all different disease states.3
However, these instruments may not capture changes relevant to asthmatics and
tend not to be very sensitive to small changes3. The limitations of generic
questionnaires have led researchers to develop disease-specific surveys. These focus
on conditions that are specific to asthmatics, such as the degree of breathlessness
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and other symptoms related to asthma. The standard asthma-specific QOL
questionnaires are the Asthma Quality of Life Questionnaire (AQLQ)3 and the Living
with Asthma Questionnaire (LWAQ).3 Both reflect small changes in asthmatics’
QOL.3
Interpretation limits the validity of all QOL questionnaires. One way to determine
the clinical significance of scores is to assess the minimal important difference - the
smallest difference in score improvement which patients perceive as beneficial and
which would mandate a change in the patient’s management.4
To promote reimbursement for cognitive services, pharmacists need to measure and
quantify their impact on QOL in conjunction with other clinical and economic
outcomes. When selecting a QOL instrument, consider the strengths and weaknesses
of each questionnaire, including its ability to detect change. Patients and their
insurance companies will be looking for measurable proof that cognitive services
have a direct positive effect on the condition of patients with asthma.
For more information contact Amy Drabinski at 973-426-6172.
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